|Title:||Acute disseminated encephalomyelitis: A follow-up study in Taiwan||Authors:||Ruey-Meei Wu
|Issue Date:||2007||Journal Volume:||78||Journal Issue:||2||Start page/Pages:||162-167||Source:||Journal of Neurology, Neurosurgery and Psychiatry||Abstract:||
Background: Acute-disseminated encephalomyelitis (ADEM) is a demyelinating disorder of the central nervous system, whose epidemiology, clinical presentations and functional outcome are incompletely understood in Asian populations. Objective: To assess the clinical presentations, predisposing factors and functional outcome of ADEM in Taiwan. Methods: 50 patients initially diagnosed with ADEM (male, 19; female, 31) were enrolled from 1991 to 2005. Diagnosis of ADEM or multiple sclerosis was established during a follow-up period of 2-120 months. 8 adult patients were noted to have taken the immunomodulatory drug, levamisole, within 3 months before onset of symptoms. The remaining 42 patients (male, 17; female, 25) were categorised by age as children (<16 years, n = 12), young adults (16-49 years, n = 21) and elderly adults (?50 years, n = 9). The clinical manifestations, predisposing factors and radiological findings were compared between different age groups and adult patients with or without levamisole use. Functional outcome was compared by a log-rank test. Results: Preceding upper respiratory tract infection was evident in 21 (50%) patients and only one young-adult patient had received Rubella vaccine immunisation. The frequency of fever was higher in children (p = 0.04) and psychiatric symptoms were more prevalent in elderly patients (p = 0.03). Functional recovery was faster in children than in adults (p = 0.002). Initial Expanded Disability Status Scale score (odds ratio (OR) 1.9, p = 0.03) and no fever (OR 0.04, p = 0.06) were associated with poor outcome (modified Rankin scale ?2). After a mean (SD) follow-up of 31.8 (9.9) months, 4 (9.5%) patients developed multiple sclerosis (3 (25%) children, 1 (4.7%) young adult, p = 0.03). The neurological disability, radiological and cerebrospinal fluid findings did not differ between patients with and without levamisole use. One elderly adult patient previously receiving levamisole developed multiple sclerosis of relapse-remitting type after a mean follow-up period of 36.9 months. Conclusion: The clinical presentations, functional outcome and risk of developing multiple sclerosis differed between different age groups. Functional recovery was faster in children than in adults. Poor functional outcome was related to initial high Expanded Disability Status Scale score and absence of fever.
|DOI:||10.1136/jnnp.2005.084194||metadata.dc.subject.other:||immunomodulating agent; levamisole; rubella vaccine; acute disease; adolescent; adult; article; cerebrospinal fluid; clinical article; clinical feature; controlled study; disease predisposition; encephalomyelitis; Expanded Disability Status Scale; female; fever; follow up; human; immunization; male; mental disease; multiple sclerosis; prevalence; priority journal; radiodiagnosis; Taiwan; upper respiratory tract infection; Adolescent; Adult; Age Factors; Child; Encephalomyelitis, Acute Disseminated; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Risk Factors; Taiwan
|Appears in Collections:||醫學院附設醫院 (臺大醫院)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.